B

BioLine RX Ltd
TASE:BLRX

Watchlist Manager
BioLine RX Ltd
TASE:BLRX
Watchlist
Price: 1.7 ILS
Market Cap: 39m ILS

Intrinsic Value

The intrinsic value of one BLRX stock under the Base Case scenario is 3.93 ILS. Compared to the current market price of 1.7 ILS, BioLine RX Ltd is Undervalued by 57%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

BLRX Intrinsic Value
3.93 ILS
Undervaluation 57%
Intrinsic Value
Price
B
Worst Case
Base Case
Best Case

Valuation History
BioLine RX Ltd

What is Valuation History?
Ask AI Assistant
What other research platforms think about BLRX?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is BLRX valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for BioLine RX Ltd.

Explain Valuation
Compare BLRX to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about BLRX?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
BioLine RX Ltd

Current Assets 28.5m
Cash & Short-Term Investments 25.2m
Receivables 699k
Other Current Assets 2.6m
Non-Current Assets 11.3m
PP&E 892k
Intangibles 10.4m
Current Liabilities 13.7m
Accounts Payable 5.7m
Other Current Liabilities 8m
Non-Current Liabilities 6.6m
Long-Term Debt 6.6m
Efficiency

Free Cash Flow Analysis
BioLine RX Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
BioLine RX Ltd

Revenue
12.7m USD
Cost of Revenue
-6.3m USD
Gross Profit
6.5m USD
Operating Expenses
-17.8m USD
Operating Income
-11.3m USD
Other Expenses
8.4m USD
Net Income
-3m USD
Fundamental Scores

BLRX Profitability Score
Profitability Due Diligence

BioLine RX Ltd's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

ROIC is Increasing
ROE is Increasing
Exceptional Gross Margin
Sustainable 3Y Average Gross Margin
25/100
Profitability
Score

BioLine RX Ltd's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

BLRX Solvency Score
Solvency Due Diligence

BioLine RX Ltd's solvency score is 45/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Short-Term Solvency
Long-Term Solvency
45/100
Solvency
Score

BioLine RX Ltd's solvency score is 45/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BLRX Price Targets Summary
BioLine RX Ltd

There are no price targets for BLRX.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

BioLine RX Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for BLRX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one BLRX stock?

The intrinsic value of one BLRX stock under the Base Case scenario is 3.93 ILS.

Is BLRX stock undervalued or overvalued?

Compared to the current market price of 1.7 ILS, BioLine RX Ltd is Undervalued by 57%.

Back to Top